Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Ajai Chari; Saurabh Chhabra; Saad Usmani; Sarah Larson; Ruben Niesvizky; Jeffrey Matous; Cristina Gasparetto; Beata Holkova; Matthew Lunning; Jason Valent; Larry D. Anderson; Chatchada Karanes; Long Kwei; Lipo Chang; Thorsten Graef; Elizabeth Bilotti; Kevin McDonagh

doi:10.1182/BLOOD.V126.23.377.377

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Ajai Chari
, Saurabh Chhabra
, Saad Usmani
, Sarah Larson
, Ruben Niesvizky
, Jeffrey Matous
, Cristina Gasparetto
, Beata Holkova
, Matthew Lunning
, Jason Valent
, Larry D. Anderson
, Chatchada Karanes
, Long Kwei
, Lipo Chang
, Thorsten Graef
, Elizabeth Bilotti
, Kevin McDonagh

Icahn School of Medicine at Mount Sinai
Medical University of South Carolina
Carolinas Healthcare System
University of California, Los Angeles
Cornell University
Colorado Blood Cancer Institute, Denver, CO
Duke University
VCU Medical Center
Cleveland Clinic
University of Texas Southwestern Medical Center
City of Hope National Medical Center
Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA.
Vanderbilt University

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	126
Issue number	23
DOIs	https://doi.org/10.1182/BLOOD.V126.23.377.377
State	Published - Dec 3 2015
Externally published	Yes

Disciplines

Immunology and Infectious Disease
Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1182/BLOOD.V126.23.377.377License: Unspecified

Cite this

Chari, A., Chhabra, S., Usmani, S., Larson, S., Niesvizky, R., Matous, J., Gasparetto, C., Holkova, B., Lunning, M., Valent, J., Anderson, L. D., Karanes, C., Kwei, L., Chang, L., Graef, T., Bilotti, E., & McDonagh, K. (2015). Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study. Blood, 126(23). https://doi.org/10.1182/BLOOD.V126.23.377.377

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study. / Chari, Ajai; Chhabra, Saurabh; Usmani, Saad et al.
In: Blood, Vol. 126, No. 23, 03.12.2015.

Research output: Contribution to journal › Article › peer-review

Chari, A, Chhabra, S, Usmani, S, Larson, S, Niesvizky, R, Matous, J, Gasparetto, C, Holkova, B, Lunning, M, Valent, J, Anderson, LD, Karanes, C, Kwei, L, Chang, L, Graef, T, Bilotti, E & McDonagh, K 2015, 'Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study', Blood, vol. 126, no. 23. https://doi.org/10.1182/BLOOD.V126.23.377.377

@article{cbff1bac3f214de9bc1684a487997b2c,

title = "Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study",

author = "Ajai Chari and Saurabh Chhabra and Saad Usmani and Sarah Larson and Ruben Niesvizky and Jeffrey Matous and Cristina Gasparetto and Beata Holkova and Matthew Lunning and Jason Valent and Anderson, \{Larry D.\} and Chatchada Karanes and Long Kwei and Lipo Chang and Thorsten Graef and Elizabeth Bilotti and Kevin McDonagh",

note = "653. Myeloma: Therapy, excluding Transplantation: Novel Drugs and Combinations | Ajai Chari, Saurabh Chhabra, Saad Usmani, Sarah Larson, Ruben Niesvizky, Jeffrey Matous, Cristina Gasparetto, Beata Holkova, Matthew Lunning, Jason Valent, Larry D.",

year = "2015",

month = dec,

day = "3",

doi = "10.1182/BLOOD.V126.23.377.377",

language = "American English",

volume = "126",

journal = "Blood",

publisher = "American Society of Hematology",

number = "23",

}

TY - JOUR

T1 - Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

AU - Chari, Ajai

AU - Chhabra, Saurabh

AU - Usmani, Saad

AU - Larson, Sarah

AU - Niesvizky, Ruben

AU - Matous, Jeffrey

AU - Gasparetto, Cristina

AU - Holkova, Beata

AU - Lunning, Matthew

AU - Valent, Jason

AU - Anderson, Larry D.

AU - Karanes, Chatchada

AU - Kwei, Long

AU - Chang, Lipo

AU - Graef, Thorsten

AU - Bilotti, Elizabeth

AU - McDonagh, Kevin

N1 - 653. Myeloma: Therapy, excluding Transplantation: Novel Drugs and Combinations | Ajai Chari, Saurabh Chhabra, Saad Usmani, Sarah Larson, Ruben Niesvizky, Jeffrey Matous, Cristina Gasparetto, Beata Holkova, Matthew Lunning, Jason Valent, Larry D.

PY - 2015/12/3

Y1 - 2015/12/3

UR - https://ashpublications.org/blood/article/126/23/377/93037/Combination-Treatment-of-the-Bruton-s-Tyrosine

U2 - 10.1182/BLOOD.V126.23.377.377

DO - 10.1182/BLOOD.V126.23.377.377

M3 - Article

VL - 126

JO - Blood

JF - Blood

IS - 23

ER -

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Disciplines

Access to Document

Other files and links

Cite this